

Global Mirabegron Sustained-release Tablets Market Growth 2026-2032

<https://marketpublishers.com/r/G5C1E8C93B62EN.html>

Date: June 2026

Pages: 125

Price: US\$ 3,660.00 (Single User License)

ID: G5C1E8C93B62EN

Abstracts

The global Mirabegron Sustained-release Tablets market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Mirabegron sustained-release tablets are designed to provide a controlled release of the medication over an extended period, which helps maintain stable levels of mirabegron in the bloodstream. This formulation is used to treat overactive bladder (OAB) symptoms, including frequent urination, urgency, and urinary incontinence.

United States market for Mirabegron Sustained-release Tablets is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Mirabegron Sustained-release Tablets is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Mirabegron Sustained-release Tablets is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Mirabegron Sustained-release Tablets players cover Astellas Pharma, Zydus Lifesciences, Lupin Pharmaceuticals, Alkem Laboratories, Chia Tai Tianqing Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Mirabegron Sustained-release Tablets Industry Forecast" looks at past sales and reviews total world Mirabegron

Sustained-release Tablets sales in 2025, providing a comprehensive analysis by region and market sector of projected Mirabegron Sustained-release Tablets sales for 2026 through 2032. With Mirabegron Sustained-release Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Mirabegron Sustained-release Tablets industry.

This Insight Report provides a comprehensive analysis of the global Mirabegron Sustained-release Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mirabegron Sustained-release Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Mirabegron Sustained-release Tablets market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mirabegron Sustained-release Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mirabegron Sustained-release Tablets.

This report presents a comprehensive overview, market shares, and growth opportunities of Mirabegron Sustained-release Tablets market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

25mg per Tablet

50mg per Tablet

Segmentation by Application:

Hospital and Clinic

Pharmacy

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Astellas Pharma

Zydus Lifesciences

Lupin Pharmaceuticals

Alkem Laboratories

Chia Tai Tianqing Pharmaceutical

Zhejiang Huayi Pharmaceutical

China Resources Pharmaceutical

Jiangxi Shanxiang Pharmaceutical

CSPC Pharmaceutical

Qilu Pharmaceutical

Jiangsu Huayang Pharmaceutical

Sichuan Gowell Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Mirabegron Sustained-release Tablets market?

What factors are driving Mirabegron Sustained-release Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Mirabegron Sustained-release Tablets market opportunities vary by end market size?

How does Mirabegron Sustained-release Tablets break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Mirabegron Sustained-release Tablets Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Mirabegron Sustained-release Tablets by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Mirabegron Sustained-release Tablets by Country/Region, 2021, 2025 & 2032
- 2.2 Mirabegron Sustained-release Tablets Segment by Type
 - 2.2.1 25mg per Tablet
 - 2.2.2 50mg per Tablet
 - 2.2.3 Mirabegron Sustained-release Tablets Sales by Type
 - 2.2.3.1 Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2026)
 - 2.2.3.2 Global Mirabegron Sustained-release Tablets Revenue and Market Share by Type (2021-2026)
 - 2.2.3.3 Global Mirabegron Sustained-release Tablets Sale Price by Type (2021-2026)
- 2.3 Mirabegron Sustained-release Tablets Segment by Application
 - 2.3.1 Hospital and Clinic
 - 2.3.2 Pharmacy
 - 2.3.3 Other
 - 2.3.4 Mirabegron Sustained-release Tablets Sales by Application
 - 2.3.4.1 Global Mirabegron Sustained-release Tablets Sale Market Share by Application (2021-2026)
 - 2.3.4.2 Global Mirabegron Sustained-release Tablets Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Mirabegron Sustained-release Tablets Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Mirabegron Sustained-release Tablets Breakdown Data by Company

3.1.1 Global Mirabegron Sustained-release Tablets Annual Sales by Company (2021-2026)

3.1.2 Global Mirabegron Sustained-release Tablets Sales Market Share by Company (2021-2026)

3.2 Global Mirabegron Sustained-release Tablets Annual Revenue by Company (2021-2026)

3.2.1 Global Mirabegron Sustained-release Tablets Revenue by Company (2021-2026)

3.2.2 Global Mirabegron Sustained-release Tablets Revenue Market Share by Company (2021-2026)

3.3 Global Mirabegron Sustained-release Tablets Sale Price by Company

3.4 Key Manufacturers Mirabegron Sustained-release Tablets Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Mirabegron Sustained-release Tablets Product Location Distribution

3.4.2 Players Mirabegron Sustained-release Tablets Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR MIRABEGRON SUSTAINED-RELEASE TABLETS BY GEOGRAPHIC REGION

4.1 World Historic Mirabegron Sustained-release Tablets Market Size by Geographic Region (2021-2026)

4.1.1 Global Mirabegron Sustained-release Tablets Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Mirabegron Sustained-release Tablets Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Mirabegron Sustained-release Tablets Market Size by Country/Region (2021-2026)

4.2.1 Global Mirabegron Sustained-release Tablets Annual Sales by Country/Region (2021-2026)

4.2.2 Global Mirabegron Sustained-release Tablets Annual Revenue by Country/Region (2021-2026)

4.3 Americas Mirabegron Sustained-release Tablets Sales Growth

4.4 APAC Mirabegron Sustained-release Tablets Sales Growth

4.5 Europe Mirabegron Sustained-release Tablets Sales Growth

4.6 Middle East & Africa Mirabegron Sustained-release Tablets Sales Growth

5 AMERICAS

5.1 Americas Mirabegron Sustained-release Tablets Sales by Country

5.1.1 Americas Mirabegron Sustained-release Tablets Sales by Country (2021-2026)

5.1.2 Americas Mirabegron Sustained-release Tablets Revenue by Country (2021-2026)

5.2 Americas Mirabegron Sustained-release Tablets Sales by Type (2021-2026)

5.3 Americas Mirabegron Sustained-release Tablets Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Mirabegron Sustained-release Tablets Sales by Region

6.1.1 APAC Mirabegron Sustained-release Tablets Sales by Region (2021-2026)

6.1.2 APAC Mirabegron Sustained-release Tablets Revenue by Region (2021-2026)

6.2 APAC Mirabegron Sustained-release Tablets Sales by Type (2021-2026)

6.3 APAC Mirabegron Sustained-release Tablets Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Mirabegron Sustained-release Tablets by Country

7.1.1 Europe Mirabegron Sustained-release Tablets Sales by Country (2021-2026)

7.1.2 Europe Mirabegron Sustained-release Tablets Revenue by Country (2021-2026)

7.2 Europe Mirabegron Sustained-release Tablets Sales by Type (2021-2026)

7.3 Europe Mirabegron Sustained-release Tablets Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Mirabegron Sustained-release Tablets by Country

8.1.1 Middle East & Africa Mirabegron Sustained-release Tablets Sales by Country (2021-2026)

8.1.2 Middle East & Africa Mirabegron Sustained-release Tablets Revenue by Country (2021-2026)

8.2 Middle East & Africa Mirabegron Sustained-release Tablets Sales by Type (2021-2026)

8.3 Middle East & Africa Mirabegron Sustained-release Tablets Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Mirabegron Sustained-release Tablets

10.3 Manufacturing Process Analysis of Mirabegron Sustained-release Tablets

10.4 Industry Chain Structure of Mirabegron Sustained-release Tablets

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Mirabegron Sustained-release Tablets Distributors

11.3 Mirabegron Sustained-release Tablets Customer

12 WORLD FORECAST REVIEW FOR MIRABEGRON SUSTAINED-RELEASE TABLETS BY GEOGRAPHIC REGION

12.1 Global Mirabegron Sustained-release Tablets Market Size Forecast by Region

12.1.1 Global Mirabegron Sustained-release Tablets Forecast by Region (2027-2032)

12.1.2 Global Mirabegron Sustained-release Tablets Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Mirabegron Sustained-release Tablets Forecast by Type (2027-2032)

12.7 Global Mirabegron Sustained-release Tablets Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Astellas Pharma

13.1.1 Astellas Pharma Company Information

13.1.2 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolios and Specifications

13.1.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Astellas Pharma Main Business Overview

13.1.5 Astellas Pharma Latest Developments

13.2 Zydus Lifesciences

13.2.1 Zydus Lifesciences Company Information

13.2.2 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolios and Specifications

13.2.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Revenue,

Price and Gross Margin (2021-2026)

13.2.4 Zydus Lifesciences Main Business Overview

13.2.5 Zydus Lifesciences Latest Developments

13.3 Lupin Pharmaceuticals

13.3.1 Lupin Pharmaceuticals Company Information

13.3.2 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product

Portfolios and Specifications

13.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue,

Price and Gross Margin (2021-2026)

13.3.4 Lupin Pharmaceuticals Main Business Overview

13.3.5 Lupin Pharmaceuticals Latest Developments

13.4 Alkem Laboratories

13.4.1 Alkem Laboratories Company Information

13.4.2 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolios

and Specifications

13.4.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Revenue,

Price and Gross Margin (2021-2026)

13.4.4 Alkem Laboratories Main Business Overview

13.4.5 Alkem Laboratories Latest Developments

13.5 Chia Tai Tianqing Pharmaceutical

13.5.1 Chia Tai Tianqing Pharmaceutical Company Information

13.5.2 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets

Product Portfolios and Specifications

13.5.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales,

Revenue, Price and Gross Margin (2021-2026)

13.5.4 Chia Tai Tianqing Pharmaceutical Main Business Overview

13.5.5 Chia Tai Tianqing Pharmaceutical Latest Developments

13.6 Zhejiang Huayi Pharmaceutical

13.6.1 Zhejiang Huayi Pharmaceutical Company Information

13.6.2 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product

Portfolios and Specifications

13.6.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales,

Revenue, Price and Gross Margin (2021-2026)

13.6.4 Zhejiang Huayi Pharmaceutical Main Business Overview

13.6.5 Zhejiang Huayi Pharmaceutical Latest Developments

13.7 China Resources Pharmaceutical

13.7.1 China Resources Pharmaceutical Company Information

13.7.2 China Resources Pharmaceutical Mirabegron Sustained-release Tablets

Product Portfolios and Specifications

13.7.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 China Resources Pharmaceutical Main Business Overview

13.7.5 China Resources Pharmaceutical Latest Developments

13.8 Jiangxi Shanxiang Pharmaceutical

13.8.1 Jiangxi Shanxiang Pharmaceutical Company Information

13.8.2 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

13.8.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Jiangxi Shanxiang Pharmaceutical Main Business Overview

13.8.5 Jiangxi Shanxiang Pharmaceutical Latest Developments

13.9 CSPC Pharmaceutical

13.9.1 CSPC Pharmaceutical Company Information

13.9.2 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

13.9.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 CSPC Pharmaceutical Main Business Overview

13.9.5 CSPC Pharmaceutical Latest Developments

13.10 Qilu Pharmaceutical

13.10.1 Qilu Pharmaceutical Company Information

13.10.2 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

13.10.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Qilu Pharmaceutical Main Business Overview

13.10.5 Qilu Pharmaceutical Latest Developments

13.11 Jiangsu Huayang Pharmaceutical

13.11.1 Jiangsu Huayang Pharmaceutical Company Information

13.11.2 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

13.11.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Jiangsu Huayang Pharmaceutical Main Business Overview

13.11.5 Jiangsu Huayang Pharmaceutical Latest Developments

13.12 Sichuan Gowell Pharmaceutical

13.12.1 Sichuan Gowell Pharmaceutical Company Information

13.12.2 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets

Product Portfolios and Specifications

13.12.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Sichuan Gowell Pharmaceutical Main Business Overview

13.12.5 Sichuan Gowell Pharmaceutical Latest Developments

13.13 Shenzhen Main Luck Pharmaceuticals

13.13.1 Shenzhen Main Luck Pharmaceuticals Company Information

13.13.2 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolios and Specifications

13.13.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Shenzhen Main Luck Pharmaceuticals Main Business Overview

13.13.5 Shenzhen Main Luck Pharmaceuticals Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Mirabegron Sustained-release Tablets Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Mirabegron Sustained-release Tablets Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of 25mg per Tablet

Table 4. Major Players of 50mg per Tablet

Table 5. Global Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units)

Table 6. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2026)

Table 7. Global Mirabegron Sustained-release Tablets Revenue by Type (2021-2026) & (\$ million)

Table 8. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2021-2026)

Table 9. Global Mirabegron Sustained-release Tablets Sale Price by Type (2021-2026) & (US\$/Unit)

Table 10. Global Mirabegron Sustained-release Tablets Sale by Application (2021-2026) & (K Units)

Table 11. Global Mirabegron Sustained-release Tablets Sale Market Share by Application (2021-2026)

Table 12. Global Mirabegron Sustained-release Tablets Revenue by Application (2021-2026) & (\$ million)

Table 13. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2021-2026)

Table 14. Global Mirabegron Sustained-release Tablets Sale Price by Application (2021-2026) & (US\$/Unit)

Table 15. Global Mirabegron Sustained-release Tablets Sales by Company (2021-2026) & (K Units)

Table 16. Global Mirabegron Sustained-release Tablets Sales Market Share by Company (2021-2026)

Table 17. Global Mirabegron Sustained-release Tablets Revenue by Company (2021-2026) & (\$ millions)

Table 18. Global Mirabegron Sustained-release Tablets Revenue Market Share by Company (2021-2026)

Table 19. Global Mirabegron Sustained-release Tablets Sale Price by Company

(2021-2026) & (US\$/Unit)

Table 20. Key Manufacturers Mirabegron Sustained-releaseTablets Producing Area Distribution and Sales Area

Table 21. Players Mirabegron Sustained-releaseTablets Products Offered

Table 22. Mirabegron Sustained-releaseTablets Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Mirabegron Sustained-releaseTablets Sales by Geographic Region (2021-2026) & (K Units)

Table 26. Global Mirabegron Sustained-releaseTablets Sales Market Share Geographic Region (2021-2026)

Table 27. Global Mirabegron Sustained-releaseTablets Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 28. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Geographic Region (2021-2026)

Table 29. Global Mirabegron Sustained-releaseTablets Sales by Country/Region (2021-2026) & (K Units)

Table 30. Global Mirabegron Sustained-releaseTablets Sales Market Share by Country/Region (2021-2026)

Table 31. Global Mirabegron Sustained-releaseTablets Revenue by Country/Region (2021-2026) & (\$ millions)

Table 32. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Country/Region (2021-2026)

Table 33. Americas Mirabegron Sustained-releaseTablets Sales by Country (2021-2026) & (K Units)

Table 34. Americas Mirabegron Sustained-releaseTablets Sales Market Share by Country (2021-2026)

Table 35. Americas Mirabegron Sustained-releaseTablets Revenue by Country (2021-2026) & (\$ millions)

Table 36. Americas Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)

Table 37. Americas Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)

Table 38. APAC Mirabegron Sustained-releaseTablets Sales by Region (2021-2026) & (K Units)

Table 39. APAC Mirabegron Sustained-releaseTablets Sales Market Share by Region (2021-2026)

Table 40. APAC Mirabegron Sustained-releaseTablets Revenue by Region (2021-2026)

& (\$ millions)

Table 41. APAC Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)

Table 42. APAC Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)

Table 43. Europe Mirabegron Sustained-releaseTablets Sales by Country (2021-2026) & (K Units)

Table 44. Europe Mirabegron Sustained-releaseTablets Revenue by Country (2021-2026) & (\$ millions)

Table 45. Europe Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)

Table 46. Europe Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)

Table 47. Middle East & Africa Mirabegron Sustained-releaseTablets Sales by Country (2021-2026) & (K Units)

Table 48. Middle East & Africa Mirabegron Sustained-releaseTablets Revenue Market Share by Country (2021-2026)

Table 49. Middle East & Africa Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)

Table 50. Middle East & Africa Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of Mirabegron Sustained-releaseTablets

Table 52. Key Market Challenges & Risks of Mirabegron Sustained-releaseTablets

Table 53. Key Industry Trends of Mirabegron Sustained-releaseTablets

Table 54. Mirabegron Sustained-releaseTablets Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Mirabegron Sustained-releaseTablets Distributors List

Table 57. Mirabegron Sustained-releaseTablets Customer List

Table 58. Global Mirabegron Sustained-releaseTablets Sales Forecast by Region (2027-2032) & (K Units)

Table 59. Global Mirabegron Sustained-releaseTablets Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 60. Americas Mirabegron Sustained-releaseTablets Sales Forecast by Country (2027-2032) & (K Units)

Table 61. Americas Mirabegron Sustained-releaseTablets Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 62. APAC Mirabegron Sustained-releaseTablets Sales Forecast by Region (2027-2032) & (K Units)

Table 63. APAC Mirabegron Sustained-releaseTablets Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Europe Mirabegron Sustained-releaseTablets Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Europe Mirabegron Sustained-releaseTablets Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Middle East & Africa Mirabegron Sustained-releaseTablets Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Global Mirabegron Sustained-releaseTablets Sales Forecast by Type (2027-2032) & (K Units)

Table 69. Global Mirabegron Sustained-releaseTablets Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 70. Global Mirabegron Sustained-releaseTablets Sales Forecast by Application (2027-2032) & (K Units)

Table 71. Global Mirabegron Sustained-releaseTablets Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 72. Astellas Pharma Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors

Table 73. Astellas Pharma Mirabegron Sustained-releaseTablets Product Portfolios and Specifications

Table 74. Astellas Pharma Mirabegron Sustained-releaseTablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 75. Astellas Pharma Main Business

Table 76. Astellas Pharma Latest Developments

Table 77. Zydus Lifesciences Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors

Table 78. Zydus Lifesciences Mirabegron Sustained-releaseTablets Product Portfolios and Specifications

Table 79. Zydus Lifesciences Mirabegron Sustained-releaseTablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 80. Zydus Lifesciences Main Business

Table 81. Zydus Lifesciences Latest Developments

Table 82. Lupin Pharmaceuticals Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors

Table 83. Lupin Pharmaceuticals Mirabegron Sustained-releaseTablets Product Portfolios and Specifications

Table 84. Lupin Pharmaceuticals Mirabegron Sustained-releaseTablets Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 85. Lupin Pharmaceuticals Main Business

Table 86. Lupin Pharmaceuticals Latest Developments

Table 87. Alkem Laboratories Basic Information, Mirabegron Sustained-release Tablets Manufacturing Base, Sales Area and Its Competitors

Table 88. Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolios and Specifications

Table 89. Alkem Laboratories Mirabegron Sustained-release Tablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 90. Alkem Laboratories Main Business

Table 91. Alkem Laboratories Latest Developments

Table 92. Chia Tai Tianqing Pharmaceutical Basic Information, Mirabegron Sustained-release Tablets Manufacturing Base, Sales Area and Its Competitors

Table 93. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

Table 94. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 95. Chia Tai Tianqing Pharmaceutical Main Business

Table 96. Chia Tai Tianqing Pharmaceutical Latest Developments

Table 97. Zhejiang Huayi Pharmaceutical Basic Information, Mirabegron Sustained-release Tablets Manufacturing Base, Sales Area and Its Competitors

Table 98. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

Table 99. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 100. Zhejiang Huayi Pharmaceutical Main Business

Table 101. Zhejiang Huayi Pharmaceutical Latest Developments

Table 102. China Resources Pharmaceutical Basic Information, Mirabegron Sustained-release Tablets Manufacturing Base, Sales Area and Its Competitors

Table 103. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

Table 104. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 105. China Resources Pharmaceutical Main Business

Table 106. China Resources Pharmaceutical Latest Developments

Table 107. Jiangxi Shanxiang Pharmaceutical Basic Information, Mirabegron Sustained-release Tablets Manufacturing Base, Sales Area and Its Competitors

Table 108. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

Table 109. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 110. Jiangxi Shanxiang Pharmaceutical Main Business

Table 111. Jiangxi Shanxiang Pharmaceutical Latest Developments

Table 112. CSPC Pharmaceutical Basic Information, Mirabegron Sustained-release Tablets Manufacturing Base, Sales Area and Its Competitors

Table 113. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

Table 114. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 115. CSPC Pharmaceutical Main Business

Table 116. CSPC Pharmaceutical Latest Developments

Table 117. Qilu Pharmaceutical Basic Information, Mirabegron Sustained-release Tablets Manufacturing Base, Sales Area and Its Competitors

Table 118. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

Table 119. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 120. Qilu Pharmaceutical Main Business

Table 121. Qilu Pharmaceutical Latest Developments

Table 122. Jiangsu Huayang Pharmaceutical Basic Information, Mirabegron Sustained-release Tablets Manufacturing Base, Sales Area and Its Competitors

Table 123. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

Table 124. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 125. Jiangsu Huayang Pharmaceutical Main Business

Table 126. Jiangsu Huayang Pharmaceutical Latest Developments

Table 127. Sichuan Gowell Pharmaceutical Basic Information, Mirabegron Sustained-release Tablets Manufacturing Base, Sales Area and Its Competitors

Table 128. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications

Table 129. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 130. Sichuan Gowell Pharmaceutical Main Business

Table 131. Sichuan Gowell Pharmaceutical Latest Developments

Table 132. Shenzhen Main Luck Pharmaceuticals Basic Information, Mirabegron Sustained-release Tablets Manufacturing Base, Sales Area and Its Competitors

Table 133. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets

Product Portfolios and Specifications

Table 134. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 135. Shenzhen Main Luck Pharmaceuticals Main Business

Table 136. Shenzhen Main Luck Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Mirabegron Sustained-releaseTablets
- Figure 2. Mirabegron Sustained-releaseTablets Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Mirabegron Sustained-releaseTablets Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Mirabegron Sustained-releaseTablets Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Mirabegron Sustained-releaseTablets Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Mirabegron Sustained-releaseTablets Sales Market Share by Country/Region (2025)
- Figure 10. Mirabegron Sustained-releaseTablets Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of 25mg perTablet
- Figure 12. Product Picture of 50mg perTablet
- Figure 13. Global Mirabegron Sustained-releaseTablets Sales Market Share by Type in 2026
- Figure 14. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Type (2021-2026)
- Figure 15. Mirabegron Sustained-releaseTablets Consumed in Hospital and Clinic
- Figure 16. Global Mirabegron Sustained-releaseTablets Market: Hospital and Clinic (2021-2026) & (K Units)
- Figure 17. Mirabegron Sustained-releaseTablets Consumed in Pharmacy
- Figure 18. Global Mirabegron Sustained-releaseTablets Market: Pharmacy (2021-2026) & (K Units)
- Figure 19. Mirabegron Sustained-releaseTablets Consumed in Other
- Figure 20. Global Mirabegron Sustained-releaseTablets Market: Other (2021-2026) & (K Units)
- Figure 21. Global Mirabegron Sustained-releaseTablets Sale Market Share by Application (2025)
- Figure 22. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Application in 2026
- Figure 23. Mirabegron Sustained-releaseTablets Sales by Company in 2026 (K Units)

Figure 24. Global Mirabegron Sustained-release Tablets Sales Market Share by Company in 2026

Figure 25. Mirabegron Sustained-release Tablets Revenue by Company in 2026 (\$ millions)

Figure 26. Global Mirabegron Sustained-release Tablets Revenue Market Share by Company in 2026

Figure 27. Global Mirabegron Sustained-release Tablets Sales Market Share by Geographic Region (2021-2026)

Figure 28. Global Mirabegron Sustained-release Tablets Revenue Market Share by Geographic Region in 2026

Figure 29. Americas Mirabegron Sustained-release Tablets Sales 2021-2026 (K Units)

Figure 30. Americas Mirabegron Sustained-release Tablets Revenue 2021-2026 (\$ millions)

Figure 31. APAC Mirabegron Sustained-release Tablets Sales 2021-2026 (K Units)

Figure 32. APAC Mirabegron Sustained-release Tablets Revenue 2021-2026 (\$ millions)

Figure 33. Europe Mirabegron Sustained-release Tablets Sales 2021-2026 (K Units)

Figure 34. Europe Mirabegron Sustained-release Tablets Revenue 2021-2026 (\$ millions)

Figure 35. Middle East & Africa Mirabegron Sustained-release Tablets Sales 2021-2026 (K Units)

Figure 36. Middle East & Africa Mirabegron Sustained-release Tablets Revenue 2021-2026 (\$ millions)

Figure 37. Americas Mirabegron Sustained-release Tablets Sales Market Share by Country in 2026

Figure 38. Americas Mirabegron Sustained-release Tablets Revenue Market Share by Country (2021-2026)

Figure 39. Americas Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2026)

Figure 40. Americas Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2026)

Figure 41. United States Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 42. Canada Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 43. Mexico Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 44. Brazil Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 45. APAC Mirabegron Sustained-release Tablets Sales Market Share by Region

in 2026

Figure 46. APAC Mirabegron Sustained-release Tablets Revenue Market Share by Region (2021-2026)

Figure 47. APAC Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2026)

Figure 48. APAC Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2026)

Figure 49. China Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 50. Japan Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 51. South Korea Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 52. Southeast Asia Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 53. India Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 54. Australia Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 55. China Taiwan Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 56. Europe Mirabegron Sustained-release Tablets Sales Market Share by Country in 2026

Figure 57. Europe Mirabegron Sustained-release Tablets Revenue Market Share by Country (2021-2026)

Figure 58. Europe Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2026)

Figure 59. Europe Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2026)

Figure 60. Germany Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 61. France Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 62. UK Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 63. Italy Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 64. Russia Mirabegron Sustained-release Tablets Revenue Growth 2021-2026 (\$ millions)

Figure 65. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Market Share by Country (2021-2026)

Figure 66. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)

Figure 67. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Market Share by Application (2021-2026)

Figure 68. Egypt Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 (\$ millions)

Figure 69. South Africa Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 (\$ millions)

Figure 70. Israel Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 (\$ millions)

Figure 71. Turkey Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 (\$ millions)

Figure 72. GCC Countries Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 (\$ millions)

Figure 73. Manufacturing Cost Structure Analysis of Mirabegron Sustained-releaseTablets in 2026

Figure 74. Manufacturing Process Analysis of Mirabegron Sustained-releaseTablets

Figure 75. Industry Chain Structure of Mirabegron Sustained-releaseTablets

Figure 76. Channels of Distribution

Figure 77. Global Mirabegron Sustained-releaseTablets Sales Market Forecast by Region (2027-2032)

Figure 78. Global Mirabegron Sustained-releaseTablets Revenue Market Share Forecast by Region (2027-2032)

Figure 79. Global Mirabegron Sustained-releaseTablets Sales Market Share Forecast by Type (2027-2032)

Figure 80. Global Mirabegron Sustained-releaseTablets Revenue Market Share Forecast by Type (2027-2032)

Figure 81. Global Mirabegron Sustained-releaseTablets Sales Market Share Forecast by Application (2027-2032)

Figure 82. Global Mirabegron Sustained-releaseTablets Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Mirabegron Sustained-release Tablets Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G5C1E8C93B62EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5C1E8C93B62EN.html>